Anonymous
Guest
Anonymous
Guest
That we get paid way more than you losers! woooohoooooo
Haha you know there is no longer onyx .. Lots all Amgen now dog.. New year agreements will be up and you will all be up for re org and firings like everyone else ... Welcome to big pharma
Second it changes we will be out...
So basically political battles between new hires from newly formed BU (CV/Onyx) vs. legacy Amgen leadership in established business units that TH has no respect for is why INBU and OBU are targets for CSO conversion in 2015?
Unfortunately yes. Until TH leaves (word is he would for a top Biopharma CEO job), Onyx will likely be given preferential treatment until then.
Team Onyx who ever you are. The reason TH is being so nice to you and why you have preferential treatment is because TH pushed hard for your acquisition and quite frankly overpaid for Onyx. You aren't a bad buy, but still haven't proven to be worth the $10B since that was based off a forecast of generating at least $2B a year. TH knows that he will look bad if you can't deliver so he is willing to give you far more resources in terms of budget and headcount for you to make those revenue numbers. Noticed I said revenue. While other legacy Amgen business units will be judge of profitability, you get the pass on that as long as you hit top line numbers for now. Much like how VB has stripped other BUs of resources for CV, you get the same benefit. This is why the OBU and INBU are being downsized because both CV and Onyx are considered growth products.
The point you are all missing is Onyx is not getting any preferential treatment. They are just operating the same way they did prior to the Amgen acquisition. Not sure why that is so confusing for many of you Amgen people. This is not uncommon when acquiring companies chose the leave the purchased company as a subsidiary versus rolling it in completely.
What's funny is the Amgen folks have some longing for the Onyx people to be part of their suffering...I guess misery loves company.
Amgen will make you miserable in 2015. Count on it. I throw all and any onyx reps under the bus. My Amgen counterparts will do the same as well. We will win this war and take back your products while they can you. We at Amgen are united to destroy all things Onyx. Get ready for some pain chumpy chump!
Amgen will make you miserable in 2015. Count on it. I throw all and any onyx reps under the bus. My Amgen counterparts will do the same as well. We will win this war and take back your products while they can you. We at Amgen are united to destroy all things Onyx. Get ready for some pain chumpy chump!
Amgen will make you miserable in 2015. Count on it. I throw all and any onyx reps under the bus. My Amgen counterparts will do the same as well. We will win this war and take back your products while they can you. We at Amgen are united to destroy all things Onyx. Get ready for some pain chumpy chump!
Amgen will make you miserable in 2015. Count on it. I throw all and any onyx reps under the bus. My Amgen counterparts will do the same as well. We will win this war and take back your products while they can you. We at Amgen are united to destroy all things Onyx. Get ready for some pain chumpy chump!
The KI franchise will get Tvec next year if it is approved. Amgen will not have oncology, just supportive care that will be going generic. More RIFs for you losers.
Amgen oncology is dead. All new therapeutic products going to Onyx. All legacy products will have biosim competition in the next few years. If you've seen the price wars in HepC, you can assume that it will be even worse with Biosims. The end of Amgen OBU is near while it's the beginning of the supportive care CSO.